The MIRROR study, an open-label pilot trial in refractory, uncontrolled gout patients, showed that pegloticase given in combination with methotrexate was safe and effective and maintained responses for 6 months after initiation. 

Dr. Rich Furie has lead a group of investIgators in reporting the significant efficacy of intravenous belimumab when added to standard of care induction therapy in patients with active lupus nephritis. This phase 3, 2-year study included 448 systemic lupus erythematosus patients with biopsy proven lupus nephritis (class III or IV +/- V) patients who required induction therapy and have a UPCR ≥1 g/g. 

Data from the Framingham Heart Study has shown that hip fracture incidence has decreased over time, probably resulting from improved lifestyle changes (less smoking and heavy drinking). 

JAMA Internal Medicine reports on a controlled clinical trial of knee osteoarthritis patients wherein meloxicam responses were not significantly or clinically superior to placebo or CBT (after placebo).

Highly purified synthetic trans-capsaicin (CNTX‐4975) injected directly into the joint reduced pain in chronic knee osteoarthritis (OA), data from the open-label phase III VICTORY-3 trial showed.

Arthritis and Rheumatology reports that a Mediterranean diet (MD) is capable of reducing the high risk of RA among women who have smoked tobacco. The results stem from the E3N Study, a French prospective cohort study that collects dietary data on 98,995 women since 1990. An MD score was derived from standardized questionnaires.

Drugs inducing lupus may account for nearly 30% of all subacute cutaneous lupus erythematosus (CLE) and up to 15% of systemic lupus erythematosus (SLE) cases. Moreover there are over 100 drugs capable of inducing drug-induced lupus erythematosus.

An analysis of a large population-based cohort of axial spondyloarthritis (axSpA) patients shows that comorbidities are common and are associated with higher disease activity and higher levels of functional impairment.

Dr. Jack Cush reviews the 2020 ACR Reproductive Health Guidelines presented all week here on RheumNow. 

In this third excerpt from the ACR guidelines on managing reproductive health issues in rheumatic disease patients, we present recommendations regarding the use of glucocorticoids and guidance on lactation and medication use post-partum.

A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.

The American College of Rheumatology (ACR) has published guidelines to manage reproductive health issues in rheumatic disease (RMD) patients before, during and after pregnancy.